Thesis (Ph.D.)--Chulalongkorn University, 2009

Objective: To evaluate the different response of serum undercarboxylated osteocalcin (ucOC) and bone turnover markers at three months after treatment with menatetrenone in Thai postmenopausal women, among differences in GGCX gene polymorphisms. Design: Prospective clinical pharmacogenetic study Method: One hundred and forty Thai postmenopausal women were enrolled to evaluate the response to 45 mg/d treatment with menatetrenone concurrently with calcium and vitamin D for 3 months. Baseline serum bone turnover markers and undercarboxylated osteocalcin (ucOC) levels were collected from all participants as well as demographic characteristics and GGCX genotyping. We evaluate the reduction from baseline of ucOC at 3 months and reduction from baseline of beta-CTx and P1NP at 1and 3 months. We compared all these parameters between different groups of GGCX genotypes (GG-group and GA+AA-group) as the main interest. Results: There are significant reduction of serum ucOC, beta-CTx and P1NP from baseline at 3 months by pair t-test and one-way repeated ANOVA analysis (p<0.001) in both GG-and GA+AA-group. But there are no significant difference when compare between genotypes (p > 0.05). There were no-serious adverse events in this study. Conclusion: Menatetrenone can effectively reduced serum ucOC as well as reduced beta- CTX and P1NP, which are the main mechanism to maintain the bone quality. GGCX polymorphism does not influence these reductions.